Pharming Group announces GRAS filing on human lactoferrin
Pharming has notified the FDA that its hLF is generally recognized as safe for use as an ingredient in functional foods.
03/01/06 Biotech company Pharming Group N.V. ("the Company") has announced that it has completed its human lactoferrin (hLF) filing for a Generally Recognized as Safe (GRAS) notification with the US Food and Drug Administration (FDA).
Pharming has notified the FDA that its hLF is generally recognized as safe for use as an ingredient in functional foods. Pharming's hLF GRAS notification has been reviewed by an independent scientific expert panel. After careful evaluation of numerous safety studies performed with Pharming's hLF as well as of published scientific data, the expert panel has concluded that hLF is safe for its intended uses.
Pharming Group N.V. is developing innovative protein products for unmet needs. The Company's products include potential treatments for genetic disorders, specialty products for surgical indications, intermediates for various applications and food products. Pharming has two products in late stage development - recombinant human C1 inhibitor for hereditary angioedema (Phase III) and recombinant human lactoferrin for use in functional foods. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products.
http://www.marketwire.com/mw/release_html_b1?release_id=104952
